Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients.

In this study, we evaluated the correlation between pre-treatment plasma fibrinogen and the burden of bone metastasis in newly diagnosed PCa patients. METHODS: A single-center retrospective analysis, focusing on prostate biopsies of newly diagnosed PCa patients, was performed. A total of 261 patients were enrolled in this study in a 4-year period. All subjects were submitted to single-photon emission computerized tomography-computed tomography to confirm the status of bone metastasis and, if present, the number of metastatic lesions would then be calculated. Clinical information such as age, prostate-specific antigen (PSA), fibrinogen, clinical T stage, and Gleason score were collected. Patients were divided into three groups: (i) a non-metastatic group, (ii) a high volume disease (HVD) group (>3 metastases with at least one lesion outside the spine), and (iii) a low volume disease (LVD) group (metastatic patients excluding HVD ones). The main statistical methods included non-parametric Mann-Whitney test, Spearman correlation, receiver operating characteristic (ROC) curves, and logistic regression. RESULTS: Fibrinogen positively correlated with Gleason score (r = 0.180, P = 0.003), PSA levels (r = 0.216, P 
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research

Related Links:

AbstractObjectiveQualitative interpretation in bone scan is often complicated by the presence of degenerative joint disease (DJD), especially in the elderly patient. The aim of this study is to compare objectively99mTc-MDP tracer uptake between DJD and osseous metastases of the spine using semi-quantitative assessment with SPECT SUV.MethodsBone scan with SPECT/CT using99mTc-MDP was performed in 34 patients diagnosed with prostate carcinoma. SPECT/CT was performed based on our institutional standard guidelines. SUVmax based on body weight in 238 normal vertebrae visualized on SPECT/CT was quantified as baseline. A total of ...
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
Ulrika Rosenström Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) could improve the diagnostic accuracy in prostate cancer (PCa). The aim of this study was to develop a PSMA/GRPR-targeting bispecific heterodimer for SPECT and positron emission tomography (PET) diagnostic imaging of PCa. The heterodimer NOTA-DUPA-RM26 was produced by manual solid-phase peptide synthesis. NOTA-DUPA-RM26 was labeled with 111In and 68Ga, with yields >98%, and demonstrated a high stability and binding specificity to PSMA and GRPR. IC50 values for natIn-NOTA-DU...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 1 August 2019Source: Inorganica Chimica ActaAuthor(s): F. Cortezon-Tamarit, A. Baryzewska, M. Lledos, S.I. PascuAbstractIn recent years, the use of metallic isotopes for nuclear imaging techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) has become an area of much interest. In particular, PET is a molecular imaging modality that relies on the detection of two antiparallel, co-linear gamma rays (511 keV) emitted when a positron undergoes annihilation with an electron. PET isotopes of interest in medical practice are numerous and thei...
Source: Inorganica Chimica Acta - Category: Chemistry Source Type: research
ConclusionsThe results of this study demonstrate the successful preparation and preclinical testing of152Tb-PSMA-617 and its first application in a patient with mCRPC. This work could pave the way towards clinical application of other Tb radionuclides in the near future, most importantly161Tb, which has promising decay characteristics for an effective treatment of mCRPC patients.
Source: EJNMMI Research - Category: Radiology Source Type: research
In this study, we compared the program output with existing estimates and with the radiological outcome. Seventy-six whole-body single-photon emission computed tomographies/x-ray computed tomography with 3,3-diphosphono-1,2-propanedicarboxylic acid from mCRPC patients were analyzed. The software identified the whole skeletal volume (SVol) and classified the voxels metastases (MVol) or normal bone (BVol). SVol was compared with the estimation of a commercial software. MVol was compared with manual assessment and with prostate specific antigen (PSA) levels. Counts/voxel were extracted from MVol and BVol. After six cycles of ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusions: This study shows that hu11B6 labeled with the low LET beta-emitting radionuclide 177Lu can deliver therapeutic absorbed doses to prostate cancer xenografts with transient hematological side-effects. The tumor response correlated with the absorbed dose both on a macro and a small scale dosimetric level. Analysis of AR staining showed that AR protein levels increased late in the study suggesting a therapeutic mechanism, a feed forward mechanism coupled to AR driven response to DNA damage or clonal lineage selection, similar to that reported in high LET alpha-particle therapy using 225Ac labeled hu11B6, however e...
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusions: In institutions without a PET/CT facility or 68Ga generator, imaging of Pca may be considered with 99mTc-PSMA provided that there is at least a SPECT technique available but most preferably a SPECT/CT machine. The use of 99mTc-PSMA with SPECT/CT may improve the management of Pca in geographic areas with limited resources.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate/GU Imaging Posters Source Type: research
539Objectives: Both, the kidneys and the bone marrow, are considered as organs at risk in Lu-177-PSMA therapy of metastasized castration-resistant prostate cancer (mCRPC). mCRPC patients often present with a high tumor load, which may affect the risk of kidney or bone marrow toxicities via tumor sink effects. The aim of this work was to assess kidney and bone marrow absorbed doses in correlation to the patient-specific tumor load. Methods: The study is based on the first cycle of 14 patients, treated with 3.7 or 6 GBq Lu-177-PSMA-DKFZ-617. Each patient received a pre-therapeutic Ga-68-HBED-CC-PSMA PET/CT, abdominal SPECT a...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Therapy II Source Type: research
Aim Combined 68Ga-PSMA-617 PET imaging and 177Lu-PSMA-617 therapy is a precise targeted theranostic approach for patients with metastatic castration-resistant prostate cancer (mCRPC). The purpose of this study was to determine whether pretherapeutic standard uptake value (SUV) in 68Ga-PSMA-617 PET could indicate the effective dose in the main organs and absorbed dose in tumor lesions. Methods After institutional review board approval and informed consent, 9 patients with mCRPC were recruited and underwent 68Ga-PSMA-617 PET/CT scans. Five patients received 177Lu-PSMA-617 (1.30–1.42 GBq, 35–38.4 mCi) and the...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Conclusions Several model systems are now available to characterize the MSC-tumour interplay in the TME. These offer early promise in establishing robust preclinical platforms for the identification of crucial molecular pathways and for the assessment of clinical efficacy of novel drugs to inhibit cancer development and progression. However, selection of the right model for a given study should be shaped on the purpose, and should also consider fixed biological, biochemical, and biophysical parameters according to the specific tumour type. Finally, in order to get reliable and useful results to be translated to the clinic...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Computers | CT Scan | General Medicine | Prostate Cancer | SPECT | Statistics | Study